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Background: As a first-line diabetes drug that is widely prescribed around the world, metformin has been
demonstrated to be effective in reducing microvascular risk, in addition to lowering glucose levels. Specifically,
metformin use has been shown to be associated with improved lipid profiles, such as increased levels of high-density
lipoprotein cholesterol (HDL-C). However, no study has been performed to examine the differential response in HDL-C
levels to metformin treatment by race/ethnicity.
Methods: Here, based on a re-analysis of the data from the Diabetes Prevention Program, which involved pre-diabetic
participants receiving 850 mg of metformin twice daily, we compared the lipid profile changes following the metformin
use. The participants were composed of 602 Whites, 221 African Americans (AAs) and 162 Hispanics.
Results: We found that the one-year metformin treatment resulted in a significant increase in HDL-C levels in Whites
(p = 0.002) and AAs (p = 0.016), but not in Hispanics. Consistently, both Whites (p = 0.018) and AAs (p = 0.020) had more
pronounced changes in HDL-C levels than Hispanics following metformin treatment.
Conclusion: This result suggests a notion that Whites and AAs are more responsive than Hispanics to one-year
metformin use in HDL-C level changes, and that racial and ethnic identity is a factor to consider when interpreting the
effects of metformin treatment on lipid profiles.
Keywords: Cholesterol, Diabetes, HDL, MetforminBackground
As a first-line drug for treating type 2 diabetes, metfor-
min has been demonstrated to be effective in glycemic
control [1], and is thus widely prescribed around the
world. In the United States, metformin is the most
commonly prescribed diabetes medication in 2010, with
more than 48 million prescriptions being filled [2].
Metformin has been shown to reduce microvascular
risk [1, 3-5], in addition to producing beneficial effects
in other diseases involving insulin resistance, such as
polycystic ovary syndrome [6] and non-alcoholic fatty
liver disease [7].* Correspondence: rzhang@med.wayne.edu
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creativecommons.org/publicdomain/zero/1.0/Diabetes is commonly associated with abnormality in
lipid profiles, characterized by increased triglycerides,
reduced HDL-C, and postprandial lipemia, known as
diabetic dyslipidemia [8-11]. Cardiovascular morbidity
and mortality are higher in patients with type 2 dia-
betes than in the general population [8, 12, 13], partly
due to accelerated development of atherosclerosis [14,
15]. In fact, the first cause of death in diabetic patients
is heart disease or stroke. Indeed, diabetes treatment
can reduce the chances of heart disease and improve
cardiovascular outcome [16, 17]. Specifically, metfor-
min treatments have been shown to be associated with
improved lipid profiles, such as reduced triglycerides
and increased HDL-C [18-25].
Because of the widespread use of metformin in the
world and the high prevalence of diabetes among dif-
ferent racial and ethnic groups, it is important to exam-
ine the racial difference in response to metforminticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Americans (AAs) have a better glycemic response to
metformin compared to European Americans [26].
Nevertheless, no study has been performed to examine
the differential response in HDL-C levels following
metformin treatment by race/ethnicity. Here, based on
the re-analysis of the data from the Diabetes Prevention
Program (DPP) [27, 28], we compared the lipid profile
changes after one-year treatment of metformin. We
found that in the metformin group, but not in the pla-
cebo group, one-year metformin increased HDL-C
levels in Whites and AAs, but not in Hispanics.Materials and methods
The DPP data Archive version 2.1 was obtained from
the National Institute of Diabetes and Digestive and
Kidney (NIDKK) data repository. The DPP was a multi-
center clinical trial examining effects of intensive
lifestyle changes or metformin versus placebo on the
rate of developing diabetes. Qualified subjects all had
prediabetes, due to elevated fasting glucose, impaired
glucose tolerance, and obesity. Informed consent was
obtained from all subjects. The metformin group re-
ceived 850 mg of metformin twice a day. Of note, the
placebo groups also received information about diet
and exercise but no intensive motivational counseling.
Forty five percent of the participants were recruited
from minority groups, such as African American,
Alaska Native, American Indian, Asian American, and
Hispanics, who have an increased risk of developing
diabetes [29]. Lipid profile measurements and lipopro-
tein subclass particle concentration determination were
performed as previously described [30].
Student t tests and ANOVA were performed to com-
pare differences in lipid levels among Whites, AAs and
Hispanics, and paired t tests were performed to com-
pare differences in lipid levels between baseline and
year-one values. A generalized estimating equation was
implemented to examine the rate of change in HDL-C
levels in response to metformin treatment, and it was
adjusted for confounding factors including age, gender,
body mass index, triglycerie, LDL-C, cholesterol and
fasting glucose levels. Average mean change from base-
line to year 1 among Whites, AAs, and Hispanic were
computed using One-way ANOVA, and Dunnett
method was performed for multiple comparison tests.
The Software SAS 9.3 (SAS Institute, Cary, NC) was
used to perform statistical tests, and P < 0.05 was con-
sidered significant. The study protocol was approved
by the Institutional Review Boards of Wayne State
University School of Medicine and of the Detroit
Medical Center, and all studies were carried out in ac-
cordance with the approved guidelines.Results
HDL-C levels are increased in the metformin group, but
not in the placebo group
The current study included 985 participants, made up of
650 females and 335 males. The distributions of age and
BMI are listed in Table 1. All DPP participants were pre-
diabetic. Consistently, at baseline, the fasting plasma glu-
cose and insulin levels were 107.25 ± 7.84 (mg/dL) and
26.99 ± 14.80 (μIU/mL), respectively, and the HbA1C
level was 5.91 ± 0.51 (%).
In the metformin group, the baseline and year-one
HDL-C levels (mg/dL) were 46.17 ± 11.58 and 46.88 ±
12.07, respectively. Compared to the baseline level, the
year-one level was significantly increased, with the average
increase being 0.67 ± 6.49 (paired t test, p = 0.002). In the
placebo group, the HDL-C levels (mg/dL) at baseline and
year one were: 44.79 ± 11.51 and 44.78 ± 11.41, respect-
ively; and the average change (−0.09 ± 6.05) between the
baseline and year one was not significant (p = 0.639)
(Table 2). Therefore, HDL-C levels were increased in the
metformin group, but not in the placebo group.
We next examined other lipid parameters following
metformin treatment (Table 2). In the metformin group,
compared to the baseline values, levels of triglycerides,
total cholesterol, VLDL and LDL-C were all significantly
reduced at year one, with changes (mg/dL) being −5.01
± 67.09 (p = 0.023), −4.62 ± 25.18 (p < 0.001), −0.98
± 13.45 (p = 0.027) and −4.27 ± 23.08 (p < 0.001), respect-
ively. Interestingly, at year one in the placebo group, the
levels of triglycerides, total cholesterol, VLDL and LDL-
C were significantly reduced as well, with changes being
−9.25 ± 73.84 (p <0.001), −4.04 ± 26.64 (p < 0.001), −1.70
± 13.97 (p < 0.001) and −2.22 ± 24.67 (p = 0.006), respect-
ively (Table 2).
We also examined the LDL-subfraction changes in
both metformin and placebo groups. Compared to the
baseline values, in the metformin group, both LDL B
subfraction (−1.59 ± 13.86, p < 0.001) and C subfraction
(−3.65 ± 20.98, p < 0.001) were decreased at year 1.
Likewise, in the placebo group, both LDL B and C sub-
fractions were decreased as well, with changes being
−1.15 ± 13.51 (p < 0.001) and −2.65 ± 21.51 (p < 0.001),
respectively. In contrast, the LDL particle size was not
significantly changed in both metformin and placebo
groups. Therefore, among different parameters in the
lipid profile, only changes in HDL-C levels were dis-
tinct between the metformin group and the placebo
group, suggesting that one-year metformin treatment
to be the factor that increased HDL cholesterol levels.
One-year metformin increases HDL cholesterol in Whites
and African Americans, but not in Hispanics
We next examined the HDL-C levels following metfor-
min treatment among different race/ethnicity. In the
Table 1 Clinical characteristics of the DPP participants treated with metformin by racial/ethnic group
Whites African Americans Hispanics All
N 602 221 162 985
Male 225 58 52 335
Female 377 163 110 650
Age (years)
< 40 65 27 36 128
40 – 49 203 79 56 338
50 – 59 197 70 50 317
> = 60 137 45 20 202
BMI (kg/m2)
< 30 181 87 45 313
30 to < 36 227 71 63 361
> = 36 194 63 54 311
Fasting plasma glucose (mg/dL) 107.05 ± 7.64 108.35 ± 8.00 106.49 ± 8.21 107.25 ± 7.84
Fasting plasma insulin (μIU/mL) 26.03 ± 14.92 28.93 ± 15.76 27.93 ± 12.62 26.99 ± 14.80
HbA1c (%) 5.80 ± 0.43 6.20 ± 0.58 5.89 ± 0.51 5.91 ± 0.51
Data for levels of plasma glucose, insulin and HbA1c are presented as means ± SD
BMI body mass index
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and 162 Hispanics, among which 377, 163, and 110
were women, respectively (Table 1). Distribution of
ages and BMIs are listed in Table 1 for different race/
ethnicity.
The HDL-C levels in the placebo group at baseline and
year one in Whites were (mg/dL, mean ± SEM) 44.8 ± 0.47Table 2 Lipid profiles in DPP participants by treatment group at bas
Group N (female) Variable Baseline
Metformin 985 (650) TRIG 157.02 ± 86.
CHOL 202.96 ± 35.
HDL-C 46.17 ± 11.5
VLDL 31.26 ± 16.9
CLDL 125.05 ± 32.
LDLB 69.58 ± 17.6
LDLC 107.67 ± 27.
LDLZ 0.27 ± 0.03
Placebo 973 (675) TRIG 167.96 ± 93.
CHOL 203.62 ± 36.
HDL-C 44.79 ± 11.5
VLDL 33.31 ± 17.7
CLDL 125.04 ± 33.
LDLB 69.56 ± 18.3
LDLC 106.48 ± 28.
LDLZ 0.26 ± 0.03
CHOL, cholesterol; HDL-C, high density lipoprotein cholesterol; LDL, low density lipo
LDL particle size; TRIG, triglycerides; VLDL, very low density lipoprotein cholesterol. D
a Paired Student t test for difference between baseline and year-one values. The oriand 44.9 ± 0.47, respectively; in AAs were 45.9 ± 0.81 and
45.9 ± 0.87, respectively; in Hispanics were 43.2 ± 0.85 and
43.0 ± 0.84, respectively (Fig. 1). The HDL-C levels in the
metformin group at baseline and year one in Whites were
45.3 ± 0.48 and 46.2 ± 0.51, respectively, in AAs were 48.5
± 0.80 and 49.7 ± 0.87, respectively, and in Hispanics were
46.1 ± 0.80 and 45.5 ± 0.89, respectively (Fig. 1).eline and one-year follow-up
Year 1 Delta P
valuea
87 152.59 ± 90.99 −5.01 ± 67.09 0.023
25 198.50 ± 34.88 −4.62 ± 25.18 <0.001
8 46.88 ± 12.07 0.67 ± 6.49 0.002
3 30.40 ± 17.85 −0.98 ± 13.45 0.027
06 120.79 ± 31.14 −4.27 ± 23.08 <0.001
7 67.97 ± 17.49 −1.59 ± 13.86 <0.001
08 103.92 ± 26.95 −3.65 ± 20.98 <0.001
0.27 ± 0.03 0.00 ± 0.02 0.761
87 159.07 ± 95.36 −9.25 ± 73.84 <0.001
35 199.67 ± 35.07 −4.04 ± 26.64 <0.001
1 44.78 ± 11.41 −0.09 ± 6.05 0.639
3 31.66 ± 18.47 −1.70 ± 13.97 <0.001
47 122.76 ± 31.21 −2.22 ± 24.67 0.006
8 68.44 ± 17.36 −1.15 ± 13.51 0.01
38 103.78 ± 27.04 −2.65 ± 21.51 <0.001
0.26 ± 0.03 0.00 ± 0.03 0.830
protein cholesterol; LDLB, LDL-B sub-fraction; LDLC, LDL-C sub-fraction; LDLZ,
ata are presented as mean ± SD
ginal abbreviations in the DPP dataset were adopted
Fig. 1 One-year metformin treatment increases HDL cholesterol in Whites and African Americans, but not in Hispanics. Levels of HDL-C at baseline and
one-year checkup in a Whites, b African Americans and c Hispanics. Paired Student t tests were performed to compare HDL-C levels in the baseline
and year-one checkup. HDL-C, high-density lipoprotein cholesterol; NS, non-significant. Data are represented as mean ± SEM
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HDL-C levels in the baseline and year-one checkup. In
the metformin group, one-year metformin treatment re-
sulted in significant increases in HDL-C levels in Whites
(p = 0.002) and AAs (p = 0.016), but not in Hispanics
(p = 0.329) (Fig. 1). In contrast, in the placebo group,
there were no significant changes in levels of HDL-C
for Whites (p = 0.564), AAs (p = 0.902), as well as for
Hispanics (p = 0.845). These results suggest that one-
year metformin treatment increased HDL-C levels in
Whites, AAs, but not in Hispanics.
Differences in change of HDL-C levels among participants
with different race/ethnicity
We next examined the changes in HDL-C levels before
and after one-year metformin treatment in both placebo
and metformin groups among race/ethnicity. The averagechanges between baseline and year one for Whites, AAs,
and Hispanics were 0.82 ± 0.26, 1.16 ± 0.48, and −0.54
± 0.55, respectively. In the placebo group, the average
changes between baseline and year one for Whites, AAs,
and Hispanics were 0.15 ± 0.26, 0.05 ± 0.44, and 0.09
± 0.46, respectively. When comparing HDL-C level
changes, in the metformin group, Whites had a more
dramatic change in HDL-C levels than Hispanics
(p = 0.018), but in the placebo group, there was no
significant difference between Whites and Hispanics
(p = 0.916) (Fig. 2). Likewise, in the metformin group,
AAs had a more dramatic change in HDL-C levels
than Hispanics (p = 0.020), but in the placebo group,
there was no significant difference between Whites
and Hispanics (p = 0.823) (Fig. 2). Therefore, both
Whites and AAs had more dramatic HDL-C level
changes than Hispanics by one-year metformin
Fig. 2 Changes in HDL-C in response to one-year metformin treatment among races. Changes = Valueone-year – valuebaseline. P values were obtained by
performing Student t tests. HDL-C, high-density lipoprotein cholesterol. Data are represented as mean ± SEM
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AAs had more HDL-C level changes than Hispanics.
To confirm these results, we also performed One-way
ANOVA to compare the changes in HDL-C in both
metformin and placebo groups among race/ethnicity.
For metformin treatment, the F value and the p value
were 3.48 and 0.031, respectively. We also took His-
panics as reference and performed multiple comparison
tests, the Dunnett method. The difference of change be-
tween Whites and Hispanics was 1.70 (95 % CI, 0.20–3.20,
p < 0.05), and the difference of change between AAs and
Hispanics was 1.36 (95 % CI, 0.08–2.64, p < 0.05). For the
placebo group, the F value and the p value were 0.08 and
0.920, respectively, by performing One-way ANOVA.
Therefore, both Whites and AAs had more dramatic
HDL-C level changes than Hispanics by one-year metfor-
min treatment, but in the placebo group, neither Whites
nor AAs had more HDL-C level changes than Hispanics.
Discussion
It was well established that HDL-C levels are associated
with other metabolism parameters, such as triglyceride and
LDL-C levels [31-34]. In addition, patients with type 2 dia-
betes are commonly associated with diabetic dyslipidemia,
characterized by high levels of triglyceride and LDL-C, butTable 3 Results of unadjusted and adjusted GEE modes for subjects
Parameter Unadjusted model




CI, confidence interval; GEE, generalized estimating equation
a Adjusted for age, gender, body mass index, triglyceride, cholesterol, LDL-C and falow levels of HDL-C [10, 35-37]. It was found that in type
2 diabetes, HDL carries higher level of sphingosine-1-
phosphate, which has the potential to contribute to
protective effects on endothelial cells by inducing the
expression of cyclooxygenase 2 [38]. Another potential
mechanism is through vitamin B12 deficiency, which is
common in type 2 diabetes, and is associated with lipid
profiles [39]. The association between insulin sensitivity
and lipid profiles is even present in heathy subjects. For
instance, it was found that in healthy hyperalphalipoprotei-
nemia subjects, several parameters that control the metab-
olism of plasma cholesterol and lipoproteins are related to
a higher degree of insulin sensitivity [36].
Because of the association between HDL-C levels and
other metabolic parameters, it is important to exclude the
effects of potential confounding factors. In statistics, a
generalized estimating equation (GEE) is used to estimate
the parameters of a generalized linear model with a
possible unknown correlation between outcomes for lon-
gitudinal data, and regression models are useful to adjust
for confounders. That is, models with covariates can
detect the effects of each covariate while the effects of
other covariates being partialed out [40]. We therefore
performed the GEE model to confirm whether the change
rate of HDL-C level over time for Whites and AAs waswith metformin treatment
Adjusted modela
P value Estimate (95 % CI) P value
0.024 1.29 (0.19–2.38) 0.022
0.019 1.38 (0.07–2.69) 0.039
- - -
sting glucose levels
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min treatment. As listed in Table 3, based on the un-
adjusted model, the slopes (Year*Race) for Whites and
AAs were 1.37 and 1.71, respectively. It means that the
change rates of HDL-C from the baseline to year one
were 1.37 mg/dL (p = 0.024) and 1.71 mg/dL (p = 0.019)
greater than that of Hispanics. Consistently, after
adjusting for covariates including age, gender, BMI, levels
of triglyceride, cholesterol, LDL-C and fasting glucose, the
rates in HDL-C changes for Whites (1.29, p = 0.022)
and AAs (1.38, p = 0.039) were still significantly greater
than that of Hispanics. Therefore, the observation that
Whites and AAs were more sensitive towards metformin
treatment in HDL-C levels than Hispanics is unlikely due
to the potential confounding factors.
One limitation of the current study is that the DPP
was not designed to examine racial differences under
interventions of metformin and life style change, and
therefore it lacked the statistical power for such ana-
lysis. To obtain significant results, we thus pooled the
data from both male and female participants, and
therefore it is unknown whether the observed differ-
ences were gender specific. Another limitation is that
the current study focuses on lipid profiles by one-year
metformin treatment, but HDL-C differences among
races in response to metformin appeared to diminish
over time. Furthermore, all DPP participants were pre-
diabetic, and therefore whether the observed racial
differences can be applied to patients with type 2 dia-
betes or other metabolic syndrome is uncertain. In
addition, the numbers of studied subjects with different
races were not well balanced, i.e., there were 602
Whites, 221 AAs and 162 Hispanics. Although the
number of 162 in Hispanics can be considered large
enough to reach statistical significance in change of
HDL-C levels, if any, it will be necessary to confirm the
observation in future studies using cohorts composed
of relatively large number of Hispanics. In addition, be-
cause of the limited number of Asians in the DPP,
Asians were not included in the current analysis.
To the best of our knowledge, this is the first report
on the differential response in lipid profile changes to
metformin treatment by race/ethnicity. Therefore, future
studies need to confirm the current observation based
on independent cohorts. Specifically, it would be import-
ant for future studies to include more time points, differ-
ent metformin doses, different races, and different
disease conditions, such as type 2 diabetes and polycystic
ovary syndrome. It would be also interesting to examine
the race-ethnicity difference in response to other dia-
betic treatments, which may be associated with distinct
lipid profile changes [41]. Another important direction is
to identify the molecular mechanisms responsible for
the racial difference in response to metformin, and theidentification of these mechanisms has the potential for
new development to increase the drug potency.
Conclusion
In conclusion, we found that in the prediabetic popula-
tion, a one-year metformin treatment raised HDL-C in
Whites and AAs, but not in Hispanics in the DPP. This
result suggests differences of HDL-C levels in response
to metformin by race/ethnicity, and that racial and eth-
nic identity is a factor to consider when interpreting the
effects of metformin treatment.
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